Stock Worth Watching: What Next for Nabriva Therapeutics AG – ADR Stock After Reaching All-Time Low?

Stock Worth Watching: What Next for Nabriva Therapeutics AG   ADR Stock After Reaching All Time Low?

The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) reached all time low today, Oct, 13 and still has $5.95 target or 13.00% below today’s $6.84 share price. This indicates more downside for the $144.16 million company. This technical setup was reported by If the $5.95 PT is reached, the company will be worth $18.74 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 10,536 shares traded hands. Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has declined 22.53% since March 10, 2016 and is downtrending. It has underperformed by 30.05% the S&P500.

Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) Ratings Coverage

Out of 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nabriva Therapeutics has been the topic of 6 analyst reports since October 12, 2015 according to StockzIntelligence Inc. The rating was initiated by Leerink Swann on Tuesday, October 13 with “Outperform”. As per Tuesday, October 13, the company rating was initiated by RBC Capital Markets. The firm has “Outperform” rating given on Tuesday, October 13 by Wedbush. On Thursday, November 12 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Monday, October 12 the stock rating was initiated by Needham with “Buy”. The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has “Buy” rating given on Wednesday, January 27 by Gabelli.

According to Zacks Investment Research, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.”

More news for Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) were recently published by:, which released: “Leerink: Time To Buy Nabriva Therapeutics’ ‘Unique Differentiation'” on October 13, 2015.‘s article titled: “Some ‘cheap’ biotech stocks that could be buyout targets, RBC says” and published on January 25, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Leave a Comment